Figure 4 | Gene Therapy

Figure 4

From: Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65

Figure 4

Dose-response of the AAV2/5-OPTIRPE65 on retinal function as demonstrated by electroretinography. Rpe65-deficient mice were injected with AAV2/5-OPTIRPE65 in one eye and with AAV2/2-hRPE65 in the contralateral eye at increasing titres. Retinal activity in the animals was assessed by dark-adapted electroretinography at 3 cd/m2. The graph shows average scotopic b-wave amplitudes (mean±s.d.) at 6 weeks post-treatment, when both vectors had reached peak expression. n=4.

Back to article page